Darzalex
E49853
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
anticancer drug
→
immunotherapy → monoclonal antibody drug → pharmaceutical drug → |
| affectsLaboratoryTest |
indirect antiglobulin test
→
|
| approvedBy |
European Medicines Agency
→
U.S. Food and Drug Administration → |
| canInterfereWith |
blood compatibility testing
→
|
| commonAdverseEffect |
fatigue
→
infusion-related reactions → nausea → neutropenia → thrombocytopenia → upper respiratory tract infection → |
| contraindication |
severe hypersensitivity to daratumumab
→
|
| developedBy |
Genmab
→
|
| firstApprovedForIndication |
treatment of patients with multiple myeloma who have received at least three prior lines of therapy
→
|
| hasActiveIngredient |
daratumumab
→
|
| hasATCCode |
L01XC24
→
|
| hasBlackBoxWarning |
infusion-related reactions
→
|
| hasDosageForm |
concentrate for solution for infusion
→
solution for subcutaneous injection → |
| hasDrugClass |
CD38-directed monoclonal antibody
→
monoclonal antibody → |
| hasInternationalNonproprietaryName |
daratumumab
→
|
| hasMechanismOfAction |
induces antibody-dependent cell-mediated cytotoxicity
→
induces apoptosis of CD38-expressing cells → induces complement-dependent cytotoxicity → modulates immune microenvironment → |
| hasRouteOfAdministration |
intravenous infusion
→
subcutaneous injection → |
| indicatedFor |
multiple myeloma
→
newly diagnosed multiple myeloma → refractory multiple myeloma → relapsed multiple myeloma → |
| marketedBy |
Janssen Biotech
→
Janssen-Cilag → |
| requiresPremedication |
antihistamines
→
antipyretics → corticosteroids → |
| targets |
CD38
→
|
| usedInCombinationWith |
bortezomib
→
dexamethasone → lenalidomide → melphalan → pomalidomide → prednisone → thalidomide → |
Referenced by (1)
| Subject (surface form when different) | Predicate |
|---|---|
|
Johnson & Johnson
→
|
notableProduct |